Literature DB >> 27064474

Post-infectious inflammatory response syndrome (PIIRS): Dissociation of T-cell-macrophage signaling in previously healthy individuals with cryptococcal fungal meningoencephalitis.

Peter R Williamson1.   

Abstract

Cryptococcus is an important cause of central nervous system infections in both immunocompromised patients such as those with HIV/AIDS as well as previously healthy individuals. Deficiencies in T-cell activation are well-known to be highly associated with host susceptibility in HIV/AIDS as well in animal modeling studies, resulting in poor microbiological control and little host inflammation. However, recent studies conducted in human patients have demonstrated roles for macrophage signaling defects as an important association with disease susceptibility. For example, an autoantibody to granulocyte monocyte stimulating factor (GMCSF) resulted in defective STAT5 signaling and susceptibility to cryptococcosis. In addition, severe cases of cryptococcal meningo-encephalitis in previously healthy patients, with or without anti-GMCSF autoantibody, developed a highly activated intrathecal T-cell population but had defects in effective macrophage polarization. Intrathecal inflammation correlated with neurological damage, measured by the axonal damage protein, neurofilament light chain 1. Based on these studies, we propose a new syndrome of cryptococcal post-infectious inflammatory response syndrome (PIIRS) defined in previously healthy patients with cryptococcal meningo-encephalitis as the presence of a poor clinical response in the setting of at least 1 month of amphotericin-based fungicidal therapy and sterile cerebrospinal cultures. These findings are discussed in light of the potential for improving therapy.

Entities:  

Year:  2015        PMID: 27064474      PMCID: PMC4825797          DOI: 10.14800/Macrophage.1078

Source DB:  PubMed          Journal:  Macrophage (Houst)        ISSN: 2378-136X


Cryptococcus neoformans is an important cause of HIV-related disease worldwide with up to a half a million deaths globally [. As highly active anti-retroviral therapy has become pervasive in developed countries such as the U.S., HIV-related disease as decreased by about half, although non-HIV related disease has remained persistent [. Mouse modeling studies have provided extensive understanding of the role of mammalian immunity to the fungus. For example, the role of innate signaling of dendritic cells by toll-receptors TLR2 and TLR9 was established in mouse models for pulmonary control of the fungus [. In addition, CD4 and CD8 cells in adaptive immunity was established in mouse pulmonary models [ as well as the role of Th1 protective immunity in neurodissemination [. More recently, the importance of the role of classically activated macrophages (M1) has been shown to be important in the control of C. neoformans infections with IL-4/IL-13 dependent alternatively activated (M2) macrophages associated with uncontrolled cerebral disease [. However, while essential and decisive for mechanistic modeling, mouse models have limitations. For example, different mouse strains have a highly variable range of immune responses to most infections. In regards to cryptococcal disease, mouse strains known to have a relative non-protective phenotype such as C57BL/6J have a greater Th2 bias than resistant strains and produce pulmonary neutrophilia and eosinophilia, which is not characteristic of human infections. In contrast, humans tend toward a histiocytic response with giant cell formation, depending on the degree of residual cellular immunity in the infected patient [. This suggests a need to conduct immunological studies in the human host during natural infections to assess species-specific immune responses. Susceptibility to human cryptococcal infections is best known to be related to T-cell defects, mediated either by HIV/AIDS-mediated depletion or that due to immune suppression by agents such as calcineurin inhibitors in organ transplant recipients [ or inflammatory disorders treated with corticosteroids. Genetic susceptibility has also been reported due to T-cell defects in Good's syndrome [ or haploinsufficiency of the hematopoietic transcription factor GATA2 [. Diseases associated with T-cell defects such as HIV have high fungal burdens due to defects in cellular immunity; and response rates have shown correlation with pathogen clearance from the cerebral spinal fluid (CSF) [. Approaches have used fungicidal drugs [ with the adjunctive Th1-polarizing cytokine interferon-γ (IFN-γ [. However, restoration of immune dysfunction in HIV-infected individuals after anti-retroviral therapy results in improved T-cell but can also produce a cryptococcal immune reconstitution syndrome (cIRIS), accompanied by increased macrophage activation that results in significant dysfunctional immune damage [. Excessive inflammatory responses are particularly damaging within the spatial confines of the central nervous system, where cerebral edema mediated by inflammation can result in neurological damage and death from brain herniation [. In addition to immunosuppressed patients, central nervous system (CNS) cryptococcal disease occurs in a significant population of previously-healthy (non-HIV) individuals and has an estimated mortality 10-30% [. Similar to the experience in HIV patients, rates of microbiological clearance predict clinical outcome [. However, the role of the immune system has not been examined in this population. This has led to conflicting approaches based on HIV paradigms, such as adjunctive IFN-γ [. Alternatively steroids has been used to suppress inflammation in non-HIV patients with C. gattii infections [. However, data is increasingly showing a role for macrophage dysfunction in susceptibility to cryptococcal infections in these apparently immunocompetent individuals. Historically, pulmonary and meningeal cryptococcal disease has been associated with pulmonary alveolar proteinosis (PAP) [, a pulmonary disease of poor secretion clearance by lung macrophages. PAP has recently been shown to be associated with autoantibodies to granulocyte-monocyte stimulating factor (anti-GMCSF) by reproducing the disease in macaques after inoculation of anti-GMCSF antibodies from human patients [. GMCSF is an important M1-polarizing cytokine which results in macrophage phagocytic and pathogen cidal actions, in addition to pulmonary secretion clearance [. Antibody to GMCSF in patients with cryptococcal meningitis results in defective signaling of STAT5 macrophage activation pathways [. Anti-GMCSF autoantibodies appear to be particularly associated with infections with a closely related cryptococcal species, C. gattii, which has resulted in a multi-year outbreak in the pacific northwest of the US and Canada [. More recently, in a cohort of CNS cryptococcal disease in previously healthy individuals, T-cell inflammation led to increased levels of detectable neurofilament light chain-1, a biomarker of axonal damage [. This leads us to call this syndrome Post-infectious Inflammatory Response Syndrome (PIIRS), defined by refractory disease constituted by continued poor or deteriorating mental status despite sterile CSF after 1 month of amphotericin-based fungicidal therapy. Interestingly, unlike other susceptible patient populations, the dendritic cell-T-cell synapse was intact, facilitating a robust IFN-γ response. Cellular and soluble markers from patients with refractory, severe CSF disease further suggested a potentially damaging immune response from T-cell activation with robust in situ expression of T-cell activation markers such as HLA-DR and soluble markers such as sCD27, IFN-γ and IL-6. However, regardless of the presence of anti-GMCSF antibody, an alternatively activated M2 macrophage phenotype was exhibited in brain tissue biopsies as well as in autopsies, demonstrated by expression of the M2 marker CD200R1 and defective expression of the M1 marker iNOS. Soluble markers of M2 activation such as IL-10 were also elevated but M1 cytokines TNF-α and IL-12 were not elevated, further suggesting an alternatively activated macrophage phenotype. In conclusion, while investigations of intracellular pathogens such as Cryptococcus has traditionally implicated defective T-cell signaling in disease susceptibility, more recently, the presence of macrophage signaling defects could define new disease types and guide rational therapeutic strategies. Furthermore, while animal studies are an important guide to potential mechanisms of disease susceptibility, studies conducted in humans may more accurately model disease susceptibilities encountered ‘in real life’ patients and help guide therapy of difficult CNS infections such as cryptococcosis.
  35 in total

1.  Pulmonary and meningeal cryptococcosis in pulmonary alveolar proteinosis.

Authors:  Y C Lee; G T Chew; B W Robinson
Journal:  Aust N Z J Med       Date:  1999-12

2.  MyD88 and TLR2, but not TLR4, are required for host defense against Cryptococcus neoformans.

Authors:  Carmelo Biondo; Angelina Midiri; Luciano Messina; Francesco Tomasello; Gabriella Garufi; Maria Rosaria Catania; Mauro Bombaci; Concetta Beninati; Giuseppe Teti; Giuseppe Mancuso
Journal:  Eur J Immunol       Date:  2005-03       Impact factor: 5.532

3.  Dissemination of C. neoformans to the central nervous system: role of chemokines, Th1 immunity and leukocyte recruitment.

Authors:  G B Huffnagle; L K McNeil
Journal:  J Neurovirol       Date:  1999-02       Impact factor: 2.643

4.  Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality.

Authors:  Nina Singh; Barbara D Alexander; Olivier Lortholary; Francoise Dromer; Krishan L Gupta; George T John; Ramon del Busto; Goran B Klintmalm; Jyoti Somani; G Marshall Lyon; Kenneth Pursell; Valentina Stosor; Patricia Munoz; Ajit P Limaye; Andre C Kalil; Timothy L Pruett; Julia Garcia-Diaz; Atul Humar; Sally Houston; Andrew A House; Dannah Wray; Susan Orloff; Lorraine A Dowdy; Robert A Fisher; Joseph Heitman; Marilyn M Wagener; Shahid Husain
Journal:  J Infect Dis       Date:  2007-01-23       Impact factor: 5.226

Review 5.  Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS.

Authors:  Benjamin J Park; Kathleen A Wannemuehler; Barbara J Marston; Nelesh Govender; Peter G Pappas; Tom M Chiller
Journal:  AIDS       Date:  2009-02-20       Impact factor: 4.177

6.  Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis.

Authors:  Takuro Sakagami; Kanji Uchida; Takuji Suzuki; Brenna C Carey; Robert E Wood; Susan E Wert; Jeffrey A Whitsett; Bruce C Trapnell; Maurizio Luisetti
Journal:  N Engl J Med       Date:  2009-12-31       Impact factor: 91.245

7.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Authors:  John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

8.  The role of CD4+ and CD8+ T cells in the protective inflammatory response to a pulmonary cryptococcal infection.

Authors:  G B Huffnagle; M F Lipscomb; J A Lovchik; K A Hoag; N E Street
Journal:  J Leukoc Biol       Date:  1994-01       Impact factor: 4.962

9.  Central nervous system immune reconstitution inflammatory syndrome.

Authors:  Nathan Bahr; David R Boulware; Suzaan Marais; James Scriven; Robert J Wilkinson; Graeme Meintjes
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

10.  Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes.

Authors:  Joseph N Jarvis; Tihana Bicanic; Angela Loyse; Daniel Namarika; Arthur Jackson; Jesse C Nussbaum; Nicky Longley; Conrad Muzoora; Jacob Phulusa; Kabanda Taseera; Creto Kanyembe; Douglas Wilson; Mina C Hosseinipour; Annemarie E Brouwer; Direk Limmathurotsakul; Nicholas White; Charles van der Horst; Robin Wood; Graeme Meintjes; John Bradley; Shabbar Jaffar; Thomas Harrison
Journal:  Clin Infect Dis       Date:  2013-12-06       Impact factor: 9.079

View more
  11 in total

1.  Immunological Predictors of Post Infectious Inflammatory Response Syndrome in HIV-Negative Immunocompetent Cryptococcal Meningitis.

Authors:  Yijie Wang; Hang Wei; Liping Shen; Xiaohong Su; Jia Liu; Xiaofeng Xu; Min Li; Lu Yang; Junyu Liu; Anni Wang; Ying Jiang; Fuhua Peng
Journal:  Front Immunol       Date:  2022-05-24       Impact factor: 8.786

2.  CD4+ T Cells Orchestrate Lethal Immune Pathology despite Fungal Clearance during Cryptococcus neoformans Meningoencephalitis.

Authors:  Lori M Neal; Enze Xing; Jintao Xu; Jessica L Kolbe; John J Osterholzer; Benjamin M Segal; Peter R Williamson; Michal A Olszewski
Journal:  MBio       Date:  2017-11-21       Impact factor: 7.867

Review 3.  Resistance and Tolerance to Cryptococcal Infection: An Intricate Balance That Controls the Development of Disease.

Authors:  Mitra Shourian; Salman T Qureshi
Journal:  Front Immunol       Date:  2019-01-29       Impact factor: 7.561

4.  Chemokine receptor CXCR3 is required for lethal brain pathology but not pathogen clearance during cryptococcal meningoencephalitis.

Authors:  Jintao Xu; Lori M Neal; Anutosh Ganguly; Jessica L Kolbe; Jessica C Hargarten; Waleed Elsegeiny; Christopher Hollingsworth; Xiumiao He; Mike Ivey; Rafael Lopez; Jessica Zhao; Benjamin Segal; Peter R Williamson; Michal A Olszewski
Journal:  Sci Adv       Date:  2020-06-17       Impact factor: 14.136

5.  Unexpected case of cryptococcal meningoencephalitis in a patient with long-standing well-controlled HIV infection.

Authors:  Hyun Ah Yoon; Paul F Riska; Ruchika Jain; Cariane Morales; Liise-Anne Pirofski
Journal:  Med Mycol Case Rep       Date:  2021-01-26

Review 6.  Post-Infectious Inflammatory Response Syndrome in an HIV-Negative Immunocompetent Elderly Patient With Cryptococcal Meningitis: A Case Report and Literature Review.

Authors:  Junyu Liu; Jia Liu; Bang-E Qin; Shiqi Yao; Anni Wang; Lu Yang; Zhihui Su; Xiaofeng Xu; Ying Jiang; Fuhua Peng
Journal:  Front Immunol       Date:  2022-02-23       Impact factor: 7.561

Review 7.  Fungal CNS Infections in Africa: The Neuroimmunology of Cryptococcal Meningitis.

Authors:  Sally H Mohamed; Tinashe K Nyazika; Kenneth Ssebambulidde; Michail S Lionakis; David B Meya; Rebecca A Drummond
Journal:  Front Immunol       Date:  2022-04-01       Impact factor: 8.786

8.  Outcomes in Previously Healthy Cryptococcal Meningoencephalitis Patients Treated With Pulse Taper Corticosteroids for Post-infectious Inflammatory Syndrome.

Authors:  Seher Anjum; Owen Dean; Peter Kosa; M Teresa Magone; Kelly A King; Edmond Fitzgibbon; H Jeff Kim; Chris Zalewski; Elizabeth Murphy; Bridgette Jeanne Billioux; Jennifer Chisholm; Carmen C Brewer; Chantal Krieger; Waleed Elsegeiny; Terri L Scott; Jing Wang; Sally Hunsberger; John E Bennett; Avindra Nath; Kieren A Marr; Bibiana Bielekova; David Wendler; Dima A Hammoud; Peter Williamson
Journal:  Clin Infect Dis       Date:  2021-11-02       Impact factor: 9.079

9.  Central Nervous System Histoplasma-Associated Post-infectious Inflammatory Response Syndrome (Histo-PIIRS).

Authors:  Owen Dean; Seher Anjum; Bryan Hess; Dima A Hammoud; Deena Athas; Joseph Wheat; Peter R Williamson
Journal:  J Clin Immunol       Date:  2021-01-02       Impact factor: 8.317

Review 10.  Cryptococcal Meningitis and Post-Infectious Inflammatory Response Syndrome in a Patient With X-Linked Hyper IgM Syndrome: A Case Report and Review of the Literature.

Authors:  Lorenza Romani; Peter Richard Williamson; Silvia Di Cesare; Gigliola Di Matteo; Maia De Luca; Rita Carsetti; Lorenzo Figà-Talamanca; Caterina Cancrini; Paolo Rossi; Andrea Finocchi
Journal:  Front Immunol       Date:  2021-07-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.